comparemela.com
Latest Breaking News On - Capsida program for genetic epilepsy due - Page 1 : comparemela.com
Capsida Biotherapeutics Presents New Preclinical Evidence Indicating Novel First-in-Class IV-Administered Gene Therapy Effectively Treats Genetic Epilepsy Due to STXBP1 Mutations
/PRNewswire/ Capsida Biotherapeutics ("Capsida") today announced new preclinical data supporting the potential of Capsida s gene therapy candidate, CAP-002,.
Mingshan-xue
Capsida-biotherapeutics
Wu-chen
Susan-catalano
Human-genetics-at-baylor-college-of-medicine
Department-of-molecular
Capsida-program-for-genetic-epilepsy-due
Baltimore-convention-center
Baylor-college-of-medicine
Department-of-neuroscience
American-society-of-gene-cell-therapy
vimarsana © 2020. All Rights Reserved.